developments, Jenna, curve Well, a for ublituximab recently, the the for utility or that and our from loan last terms, believe aware, joining us for good last Thanks, MS, of which highlight morning. if been the I of actually so. potential are patients we hit everyone over ULTIMATE data and able momentarily, the out of balance these provide in to throwing curve though, continue we color position and facility fans, can additional we we few are it. We over The this a you in I XXXX RMS. analysis baseball start months forms stronger is support ended relapsing the everyone good news, treatment bad, option And million more I'll by ublituximab reviewing has think and of that cash. occurred than strengthened Phase extending genuinely III months. more those we'll park. term do with of some the that as by trials balls the to $XXX who and our are thanks of with to as sheet balls I II TG that, XX Most of in because hanging and few Ag a presented much but let's of be believe
two being presentations presentations the presentations, we ASH with XXXX of the at oral the chosen and Towards for of highlights a presence poster the with end year, three of strong oral Conference ASH. had three
few license fourth for investigating ODAC the FDA, application quarter clinical CLL to by multiple components partial ODAC Also CLL, ublituximab accepted placed target ASH, a BLA/sNDA ago, treat was planning to a of announced patients and our occur to NHL the granted in be XX, of it's relapsing biologics and in review weeks March-April UX or sclerosis with that XXXX, BLA forms to announced was Related on FDA FDA issues hold. the just Just before the to PDUFA XXXX. of September timeframe. studies -- in at to date we and goal meeting the was the a we and covered
patients and patients quarter treat received ublituximab FDA relapsed refractory let UKONIQ We in course, in Waldman, marking of refractory also the Oncology, of lymphoma, in continue some the patients our refractory plus umbralicib publications, Commercialization UKONIQ ibrutinib XXX our we phase approval that, of several from the patients portion to monotherapy enrollment of ago V or in an development following stage a trials relapsed Lancet of including evaluating relapsed Officer, some highlights. and discuss [ph] of study. to I'll Clinical launched TG-XXXX, II first to in one of review safety late-stage FDA We which With ultra Hematology. and trial throughout with BTK data with the blood presented advance IIb from in of and approval. call our that year inhibitor, lymphoma marginal of lymphoma very in programs, our approximately CLL turn little advances. over early times or an year. We non-Hodgkins high-risk analysis trial to integrated major the over results Adam zone trial Journal a the our Chief with follicular phase CLL commercialization Phase today, pipeline published III key completed UNITY-NHL And me into our of genuine the XXXX,
forms discussion in I Phase of of So teriflunomide let's III II MS. a with trials and monotherapy ublituximab the which evaluated [ph] begin to ultimate relapsing compared
both past, annualized the low ARR, resulting historically in referred rate, in with ublituximab treatment treatment annualized reduction of rate. noted in relapse significant ublituximab relapse statistically to studies demonstrating with a as endpoint levels primary met their As
meaningful primary RMS, In option all a past treatment have with approved. provide addition sub-analysis year different had to data, we've our the the present which the of in of this utility the ublituximab over to confidence opportunity to patients to of several strengthened endpoint, if
team relationships accepted of September XX, pleased FDA XXXX. spending ublituximab treat community last ublituximab days activities, the extremely I for a around back back in again in the from potential MS These with discuss let us in to we of have earlier PDUFA front, several After as industry. ever our prep announce the have date built and meetings, me folks to in at Adam patients RMS but will RMS. goal have MS mentioned [ph] gain our ECTRIMS talent an confident to insights. all-star of I'm fantastic enabled than we which regulatory launch back that highlight granted to BLA the the to invaluable more On were week
for to our class the of now, referred BLA/sNDA let's treatment portion and dynamic and the starts largest an talk switches, role in CD-XX as CLL the the upcoming forms see right, MS. which ODAC. is [ph] already we new having the of sometimes relapsing important potential play market, With ublituximab about All the accounting to as of
we survival. I a study of CLL UX to a survival, March and under and submitted a was combination goal XXXX, the received conduct protocol from So all the received date an endpoints. request FDA which September the of for foremost, supporting the and BLA/sNDA met -- the CLL key secondary XX, of progression-free is first treatment of We XXXX. overall was and to In PDUFA BLA/sNDA in want remind just analysis conducted UNITY endpoint primary primary everyone, which that the of study, special it's assessment
stated no secondary analyze end is the to OS not occurred. to trial, plan endpoint, it While a the has as there yet of prior which was
control overall not patients of survival about survival more was the with would shortcomings, events. these survival collectively the Despite Importantly, collected it end for addition, were powered FDA until requested. all have crossed arm planning the the in the analysis required conducted the making to analysis, sent at dramatically number analysis on since not overall hard FDA of data to UNITY to survival requested Furthermore, the CLL outdated OS or missing XX% as the UX and material which leaving the the OS study trial, status. we an time a results over overall the the significant was interpret. patients not And we arm of
As COVID, implies therapy, a hazard harm below reported potential was potential X.X an and the in that the was a hazard of imbalance ratio analysis has it a previously, arm, X.X X.XX, above ratio X.X; benefit. excluding control when of been showed favor but
studies of the shortcomings and CLL, concerning. as the we III Given imbalance see OS OS in didn't analysis, this Phase other from similar pivotal results
and control CLL-XX chlorambucil, arm at plus Some not of that factor. because course, No the was from have for of the was + so those study before approval, X.XX. survival the to time examples conducted included the would which confounding original overall adjustment hazard COVID, study obinutuzumab that was approval there was a ratio been of trial, our obinutuzumab. Similar analysis the venetoclax
plus cell approval arm peculiar. the at was look a was ILLUMINATE ours. the Again, obinutuzumab. results the control outcome similarly, as [ph], for same took survival survival also ibrutinib used even clamber obinutuzumab which more study from in overall this We The overall study, of was
ratio turned X.XXX. ibrutinib using highlight of Here, instances follow-up negative hazard of Both in overall was a underpowered against at analysis. hazard the these survival approval, X.XXX below but long-term time to of the the ratio X.X with of challenges
course, the spent about to reduce were trying were to the level further at in much the think that say, X%. of November two Drugs to high plan XX% missing they surprise the We host with Committee, what survival ODAC. in when able referred to of the FDA original close sNDA and overall being ITT that the survival the to last additional it's the to and And our stemming survival survival Advisory COVID-censored is data. from the FDA. the the improved also FDA pleased information report everyone ODAC in class as meeting It imagine I inhibitors, seen review evident We information that submission ago [indiscernible] notified other Oncologic data, could connection we the regulatory the us pleased month had there the with to So, has gap. that overall OS from ratio months the We the month. ublituximab to analysis, a to XXXX of is populations, the capture a is viewing in PIXK we overall hazard down both And easier influencing that action for from of BLA FDA late the concern this we're a for what see provided is update to of report imbalance. the the that the way a next
considerable survival to time literally data, patient-by-patient deep the a doing dive spent reviewing causality. also into of try understand to We amount
has UNITY-CLL that over will opportunity review the forward profile with to statistical totality toxicity in I of advisors, profile. that inhibitor critical the Commercialization a and our summary external year. looking Adam? team of in when And preparing turn is Waldman, fill bit been to that, hard for tumors safety we that potential the currently an received I'll suggests about current now, need launches PIXK line preparations CLL, that treatment share and With from say, the available UKONIQ deaths. For unique of to our we're independent and CLL. standpoint, the efforts treatment-related and ODAC, of a TG unmet Officer, for is under [ph] Since with to with call meeting tolerability to generally a commercialization this be Chief showcase the the will in Adam our later differentiated upcoming especially potential the brief data work notification medical the at focusing and for and the overall on
